Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
NCT00964171
Interventional
Phase 2
Unknown status
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with metastatic pancreatic cancer.
Aug 31,2008
All
18 Years
N/A
18 Years
N/A
72